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Deploying clinical grade magnetic nanoparticles with magnetic fields to 
magnetolabel neural stem cells in adherent versus suspension cultures. 
D. Weinberga b, C. F. Adamsa and D. M. Charia b  
Neural stem cells (NSCs) have a high therapeutic potential for patients with 
neurological disease/injury given their neuroregenerative and immunomodulatory 
capabilities. In recent years, magnetic nanoparticles (MNPs) have been used as 
contrast agents in translational studies, to track transplanted NSCs using non-invasive 
magnetic resonance imaging (MRI). However, NSC uptake of MNPs is inherently low 
in the absence of chemical/biological uptake enhancing strategies such as cell 
targeting peptides and transfection agents – approaches which may be cytotoxic and 
alter cellular physiology. By contrast, physical delivery strategies relying on magnetic 
assistive methods can safely enhance MNP uptake into multiple neural cell types. The 
utility of this approach has been demonstrated for gene delivery grade particles but 
their application in enhancing ‘magnetolabelling’ with clinical grade contrast agents 
has never been evaluated. Here, we show that applied oscillating magnetic fields can 
safely enhance the uptake of a clinical grade MNP (Lumirem/Ferumoxsil) into NSCs 
propagated as neurospheres (suspension cultures, the preferred format for 
transplantation) but offer limited benefit for monolayer (adherent) cultures. This 
physical delivery method therefore has potential to facilitate cell labelling for clinical 
therapies.  
Introduction 
Neurodegenerative diseases and injuries are highly 
debilitating, with current treatment options limited 
largely to offering symptomatic relief as opposed to 
disease-modifying benefits.1 Neural stem cell (NSC) 
transplant populations offer important therapeutic 
potential for such patients, mediating repair in multiple 
pre-clinical disease models including Parkinson’s 
disease, multiple sclerosis and stroke2,1 with multiple 
clinical trials underway. NeuralStem (USA) is currently 
undertaking a phase I clinical trial (NCT01348451) for 
amyotrophic lateral sclerosis. The therapy was deemed 
safe,3 and NeuralStem have since initiated a phase II 
clinical trial in May 2013 (NCT01730716). ReNeuron 
(UK) is investigating the transplantation of NSCs in 
patients with ischaemic stroke, recently launching a 
phase II clinical trial (NCT02117635) at 10 UK centres. 
The ‘homing’ ability of NSCs towards sites of 
inflammation and pathology (termed ‘pathotropism’)4,5 is 
being exploited in patients with recurrent high-grade 
gliomas at City of Hope Medical Center (California, 
USA), utilising NSCs expressing the pro-drug activating 
enzyme cytosine deaminase to induce tumour shrinkage 
(NCT01172964).6 With regard to NSC transplantation 
for such patients, an important limitation remains – 
namely the need for safe, real time in vivo tracking 
methods to correlate delivery of therapeutic NSCs with 
neurological outcomes.7 Such information can facilitate 
successful cell delivery and provide valuable prognostic 
information with regard to cell proliferation and 
migration.8,9 Additionally, the migratory efficacy of 
MNP-labelled NSCs towards lesions may differ between 
delivery routes, hence information on cell biodistribution 
could be utilised to determine optimal delivery routes and 
cell retention at sites of pathology.7  
 Magnetic nanoparticles (MNPs) are evolving as 
advanced materials for multiple biomedical applications 
including gene and drug delivery,10 magnetic 
hyperthermia,11 magnetic manipulation and targeting,12 
and cell tracking.7 The iron oxide core of MNPs (usually 
magnetite or maghemite)10 enables tracking of MNP-
labelled cells using magnetic resonance imaging (MRI), 
which is clinically advantageous due to its non-
invasiveness, high spatial resolution and absence of 
ionising radiation.7 Further, MRI displays oedematous 






























































ARTICLE Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
Figure 1. Schematic diagram outlining the 
advantages/disadvantages of monolayer and neurosphere culture 
formats for NSCs. 
and inflammatory pathology to provide important clinical 
prognostic information.7 A major translational barrier 
however is that MNP uptake into NSCs is inherently low 
(10-20%)13 without increasing MNP 
concentrations/incubation times or the use of biochemical 
adjuncts including cell-penetrating peptides and 
transfection agents (TAs). These can alter cell physiology 
and TAs carry a significant toxicity risk and can cause 
MNP agglomeration.14,9 This is problematic for cell 
tracking as membrane adherent MNP aggregates may 
become detached post-transplantation, with inaccurate 
representations of transplant distribution.14 As a further 
example, heparin and protamine are two clinically-
approved transfection agents widely used to enhance 
ferumoxytol uptake into cells.15,16 The heparin 
constituent of this so-called ‘HPF complex’ may 
potentially be hazardous in causing microhaemorrhage 
following breakdown of complexes. Furthermore, this 
could disrupt haemostasis mechanisms following 
transplantation and potentially lead to local haemorrhage, 
of concern from a clinical perspective.17A potential 
solution to these translational challenges is a recent 
innovation in nanotechnology using magnetic assistive 
technology (applied static/oscillating magnetic fields) to 
safely enhance cellular MNP uptake. Magnetic assistive 
methods offer multiple advantages for translational 
neurology and transplant populations. They have been 
shown to be safe18–21 as they exploit endogenous 
endocytic machinery of cells and leave minimal residual 
toxic effects following transplantation, as opposed to the 
use of TAs. These methods are also relatively 
straightforward compared to other biochemical strategies, 
simply necessitating application of MNPs to cells in the 
presence of a magnetic field.  
We have previously proved that oscillating magnetic 
fields can enhance uptake of transfection grade MNPs 
into major neural cell types including NSCs,20 
oligodendrocyte precursor cells18 and astrocytes22 and 
enhance uptake of polymeric MNPs in NSCs.23 However, 
to our knowledge, the utility of this approach has never 
been evaluated for uptake of clinical grade MNP contrast 
agents into neural transplant populations, specifically 
NSCs. It is important to address this issue, as the the 
efficacy of magnetic assistive methods with  MNPs is 
dependent on a range of physicochemical parameters 
including particle size/density, Fe content and  fluid 
viscosity.23 Particle uptake by cells also depends on 
several parameters such as particle aggregation, size, 
surface chemistry and charge. As transfection/contrast 
grade MNPs show considerable heterogeneity in their 
physicochemical properties, it is essential to 
systematically investigate the efficacy of magnetic 
assistive technology on a particle by particle basis but 
little information  currently exists on the influence of 
MNP chemistry on uptake into neural cells.  Here, we 
have investigated the effects of oscillating magnetic 
fields on uptake of a clinical grade contrast agent 
(Lumirem/Ferumoxsil) into NSCs. Lumirem is clinically 
approved as a contrast agent for bowel imaging and 
contains siloxane-coated superparamagnetic iron oxide 
nanoparticles (SPIONs) with a reported hydrodynamic 
diameter of 300 nm.24 The siloxane coating is poorly 
soluble, protecting the iron oxide core from degradation 
and potential cytotoxicity.25 
 It is important to note here that NSCs are propagated 
by two well characterised and globally used culture 
formats- adherent ‘monolayers’ and suspension 
‘neurospheres’, both offering distinct advantages for cell 
labelling and transplantation (summarised in Figure 1).26 
For example, transplantation of neurospheres is thought 
to result in higher survival rates than single cells.27 
However, monolayer culture allows all the cells to be 
exposed to particles, potentially facilitating greater 
particle uptake throughout the cell population when 
compared to neurosphere culture (which contains 
‘hidden’ cells inside the sphere). As either system may be 
used to culture human NSCs for clinical application,28 it 
is imperative that magnetolabelling procedures are 
evaluated between the two culture formats, for 
translational studies. However, to the best of our 
knowledge, such a comparative labelling analysis has not 
been conducted previously. Given these knowledge gaps, 
the study goals were as follows (i) to determine whether 
applied oscillating magnetic fields can enhance Lumirem 
uptake in primary NSCs; (ii) to establish whether this 
combined approach is safe for NSCs; (iii) to evaluate the 
influence of NSC culture format on labelling efficacy by 
directly comparing Lumirem uptake in monolayers 
versus neurospheres. 
Materials and Methods 
Reagents 
Thermo scientific Nunc culture plates (non-treated 
surface) and other cell culture grade plastics were 
purchased from Fisher Scientific, UK. Cell culture 
reagents were purchased from Life Technologies 
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(Paisley, Scotland, UK) and Sigma (Poole, Dorset, UK). 
Human recombinant basic fibroblast growth factor 
(bFGF) was also from Sigma and human recombinant 
epidermal growth factor (EGF) from R&D Systems 
Europe Ltd (Abingdon, UK). Penicillin and streptomycin 
were from Fisher (Loughborough, UK). Accutase was 
from Sigma and DNaseI was from Roche (Welwyn, UK).  
 Lumirem was purchased from Guerbet (Solihull, UK). 
The magnefect-nano oscillating magnetic array system, 
used for oscillating magnetofection methods, was from 
nanoTherics Ltd. (Stoke-on- Trent, UK; commercially 
available since 2009). This system allows culture plates 
to be placed over a horizontal array of neodymium 
(NdFeB) magnets, grade N42, which match the plate 
configuration. The magnetic array can be programmed to 
oscillate laterally beneath the culture plate via a 
computerized motor; both the frequency (up to 5 Hz) and 
the amplitude (10 µm to 1 mm) of oscillation can be 
varied. The field strength at the face of each magnet is 
421 ± 20 mT (nanoTherics Ltd., personal 
communication). In static mode (frequency, F = 0 Hz), 
this system has been shown to produce similar 
transfection efficiencies to commercially available 
magnetic plates in routine use for static magnetofection 
and (to our knowledge) it is the only commercially 
available device for oscillating magnetofection 
applications. 
 Primary antibodies were for nestin (a NSC 
cytoskeletal protein) from BD Biosciences (Oxford, UK), 
sox-2 (a NSC transcription factor) from Millipore 
(Watford, UK), β-tubulin (TUJ-1, detects neurons) from 
Covance (Princeton, NJ, USA), glial fibrillary acidic 
protein (GFAP, detects astrocytes) from 
DakoCytomation (Ely, UK), and myelin basic protein 
(MBP, detects oligodendrocytes) from Serotec 
(Kidlington, UK). FITC-conjugated secondary antibodies 
were from Jackson Immunoresearch Laboratories Ltd 
(West Grove, PA, USA). Chemicals for Perls’ stain were 
purchased from Sigma. 
 The care and use of all animals used for cell culture 
were in accordance with the Animals Scientific 
Procedures Act of 1986 (UK) and following local ethical 
approval. 
MNP Characterisation 
When exposed to culture medium, MNP 
physicochemical properties (such as size and surface 
chemistry) can change due to particle aggregation and 
formation of a ‘protein corona’ around the particle.29 As 
both size and surface charge could affect particle 
interaction with the cellular membrane and, ultimately, 
cellular uptake, the hydrodynamic diameter and zeta 
potential of Lumirem (which has not been fully 
characterised previously) were measured. This was 
performed in both PBS and monolayer medium (ML-M) 
in which NSCs are propagated, using a Zetasizer Nano 
ZS (Malvern, UK). Briefly, MNPs were added at a 
concentration of 10 µg/ml iron to either PBS or ML-M 
and left to incubate at 37°C, 5% CO2 (24 hour samples) 
or added just prior to Zetasizer measurements in pre-
incubated media (5 minute samples). To further assess 
particle size and shape, particles were placed in pure 
water, air-dried onto aluminum stubs, and observed 
uncoated using a high-resolution field emission scanning 
electron microscope (Hitachi S4500) operated at an 
accelerating voltage of 5 kV. 
NSC culture 
NSCs were maintained and selectively expanded in 
suspension under stimulation from growth factors, to 
form neurospheres. Briefly, NSCs were derived from the 
subventricular zone of postnatal day 1-3 CD1 mice. 
Following isolation, NSCs were maintained in 
neurosphere medium (NS-M) comprising a 3:1 mix of 
DMEM:F12 containing 2% B-27 supplement, 50 U ml-1 
penicillin, 50 mg ml-1 streptomycin, 4 ng ml-1 heparin, 20 
ng ml-1 bFGF and 20 ng ml-1 EGF. NSCs were fed every 
2-3 days and neurospheres were passaged every 5-7 days 
by dissociation, both mechanically and using an 
accutase-DNaseI mix. For neurosphere labelling, NSCs 
(passages 1-3) were dissociated and plated in suspension 
at a cell density of 5 x 104 cells/ml (500 µl/well) using 
NS-M in Nunc 24 well non-treated culture plates. For 
labelling NSCs as monolayers, NSCs were re-plated in 
Nunc Nunclon Delta 24 well plates at a density of 7 x 104 
cells/ml (600 µl/well) using ML-M comprising a 1:1 mix 
of DMEM:F12, containing 1% N2 supplement, 10 ng ml-
1 bFGF and 10 ng ml-1 EGF with above antibiotic and 
heparin concentrations. NSCs in both culture formats 
were plated for 24 h prior to Lumirem addition. 
MNP incubation protocol 
A range of concentrations (2-32 µg/ml iron) were 
initially trialled for labelling of NSCs in both monolayer 
and neurosphere culture formats. Concentrations of 2-8 
µg/ml iron resulted in inefficient levels of uptake and 
those above 12 µg/ml iron led to loss of NSC adherence 
and cytotoxicity, determined by the presence of pyknotic 
nuclei and cell loss. Hence, a concentration of 10 µg/ml 
iron was used for final experiments. Lumirem MNPs 
were added in a drop-wise fashion to neurospheres whilst 
gently swirling the culture plate. For monolayers, 
Lumirem MNPs were added to NSCs in fresh ML-M. For 
each culture system, plates contained wells with treated 
and untreated cells (controls) and were incubated under 
no-field or magnetic field application. Plates undergoing 
oscillating magnetic field stimulation were added to the 
oscillating magnefect-nano device immediately following 
MNP addition for 30 minutes (frequency = 4 Hz). This 
frequency was adopted for experiments as it has 
previously been shown to be optimal for transfection of 
neurospheres with transfection-grade MNPs; static fields 
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were not used in these experiments as these have been 
shown to be without effect on  neurospheres.19, 20 Cells 
were incubated at 37°C, 5% CO2 for 48 hours prior to 
carrying out microscopic analyses. 
Neurosphere dissociation and plating as monolayers 
Following 48 hours incubation of neurospheres with or 
without Lumirem, neurospheres under different 
treatment/magnetic field conditions were dissociated as 
described above, and re-plated as 2D adherent 
monolayers onto coverslips coated with poly-L-ornithine 
and laminin. NSCs were left to adhere overnight for 18 
hours before fixing for subsequent staining and analysis. 
For NSCs undergoing differentiation, dissociated cells 
were re-plated as described above, using differentiation 
medium (NS-M without growth factors, supplemented 
with 0.5% fetal bovine serum). NSCs were differentiated 
for 5-7 days with 50% medium changes every 2-3 days. 
Immunocytochemistry and Perls’ staining 
NSCs labelled as neurospheres were fixed at 18 hours 
following dissociation, and those labelled as monolayers 
were fixed at 48 hours following MNP incubation. NSCs 
were fixed using 4% paraformaldehyde for 15 minutes at 
room temperature (RT) and then washed three times with 
PBS. For analysis of Lumirem uptake in NSCs, cells 
were stained with Perls’ Prussian Blue (20 minutes, RT). 
Perls’ stain was prepared by mixing equal volumes of 4% 
HCl with 4% potassium ferocyanide. Stained cells were 
washed twice with PBS, counterstained with 1% neutral 
red before dehydration (30 seconds in 100% ethanol 
followed by 30 seconds each in two xylene washes) and 
mounting using DPX. For immunocytochemistry, 
coverslips were blocked (5% normal donkey serum in 
PBS-0.3% Triton-X-100) for 30 minutes at RT. Primary 
antibodies were diluted in blocking solution as follows 
before addition to cells: nestin 1:200 (NSCs), sox-2 
1:100 (NSCs), TUJ-1 1:1000 (neurons), GFAP 1:500 
(astrocytes), MBP 1:200 (oligodendrocytes). Following 
overnight incubation at 4°C, cells were washed with PBS 
and blocked (30 minutes, RT). Secondary FITC-
conjugated antibodies were added in blocking solution 
(1:200) for 2 hours (RT), and then washed with PBS. 
Immunostained samples were mounted with Vectashield 
mounting medium containing DAPI. 
Microscopy and labelling analysis 
The safety of labelling NSCs with Lumirem was assessed 
in two ways: (i) following Lumirem incubation with 
neurospheres, (ii) post-fixation of dissociated NSCs 
plated as monolayers. Phase-contrast microscopy of live 
neurospheres was performed following 48 hours 
Lumirem incubation prior to neurosphere dissociation 
using a Leica DM IL LED inverted microscope (Leica 
Microsystems, Wetzlar, Germany). Two fields were 
captured from four separate wells using a FC420C digital 
camera and Leica Applications Suite software (version 
3.4.0) and then analysed in ImageJ for neurosphere 
counts per field and neurosphere size. Neurospheres with 
a diameter of <30 µm were excluded from these analyses 
as these were immature neurospheres, and generally 
difficult to discriminate as clusters of NSCs as opposed 
to cellular debris.  
 Perl’s and immunostained samples were imaged using 
an Axio Scope A1 fluorescence microscope (Carl Zeiss 
Microimaging, Germany). Perls’ stained and DPX 
mounted NSCs were imaged at 100x magnification and 
these images used for analysis in ImageJ. Analyses of 
Lumirem uptake were performed on >35 cells over three 
fields from three replicate coverslips. Images of 
immunostained NSCs and daughter cell types were also 
analysed in ImageJ to assess NSC ‘stemness’ and 
differentiation potential respectively. Here, >100 DAPI-
stained nuclei were assessed over three replicate 
coverslips for all analyses. These images were used to 
carry out cytotoxicity analyses by counting pyknotic 
(nuclear shrinkage, fragmented chromatin) DAPI nuclei 
for each condition. 
Statistical analysis 
All data were analysed using GraphPad Prism statistical 
analysis software (version 6.0) and are expressed as 
mean ± SEM unless stated otherwise. The number of 
experiments (n) refers to the number of NSC cultures, 
each derived from a different litter. 
Results 
MNP Characterisation 
Zetasizer measurements of the particles in PBS and ML-
M revealed a mean size of about 560 nm and no 
significant aggregation, or change in surface charge, of 
the particles over 24 hours (Figure 2A). A small increase 
was observed at 5 minutes in ML-MM, however at the 
longer time point of 24 hours, no significant particle 
aggregation could be noted for particles in ML-MM 
compared with PBS. SEM of particles revealed a 
spherical shape and confirmed they were within the size 
range measured by dynamic light scattering (DLS), with 
some variation in size apparent (Figure 2B).  
Lumirem labelling of NSCs as monolayers is ineffective 
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Figure 2. (A) Summary of Lumirem MNP zetasizer 
characterization (mean ± SD). (B) SEM micrograph of Lumirem 
particles. 
Figure 3.  (A) Representative image of NSCs cultured as 
monolayers after Lumirem labelling under an oscillating (F = 4 
Hz) magnetic field. Note significant MNP aggregation of particles 
(inset) including in the extracellular space (white arrow) and on 
NSC membranes (yellow arrow) with extensive cell loss (red 
circles) in this condition. Neurospheres labelled with Lumirem 
under the (B) oscillating magnetic field and (C) no field 
conditions. Note that labelling appears to be within the central 
two-thirds of the spheres. Insets in (B) and (C) show dissociated 
Perls’ stained NSCs derived from neurospheres labelled under 
oscillating magnetic field and no field conditions respectively. (D) 
Bar chart displaying quantification of the percentage of labelled 
cells after dissociation of labelled neurospheres. Statistical 
differences are: **p < 0.01 (unpaired two-tailed t test, n=4). 
After adding MNPs to NSCs cultured as monolayers, 
extensive aggregation of MNPs and the formation of 
chain-like structures were noted (Figure 3A, inset). This 
was evident when NSCs were labelled under stimulation 
by the oscillating magnetic field.  There was little 
evidence of MNP uptake into cells. Further, marked cell 
loss was apparent in these experiments, and the 
remaining adherent cells frequently displayed abnormal 
cellular morphologies (evidence of cellular rounding up, 
shrinkage or shortened cell processes compared to 
control) (Figure 3A).  
Lumirem uptake into neurospheres is enhanced by 
applied oscillating magnetic fields 
For neurospheres, incubation with Lumirem resulted in 
100% of neurospheres displaying some labelling, which 
was denser within the central two-thirds of the spheres 
(Figure 3B). Compared with the no field condition, 
neurospheres labelled under the 4 Hz field appeared more 
densely labelled (Figures 3B-C); therefore, spheres were 
dissociated in order to assess the numbers of labelled 
cells in each condition. After dissociation, the percentage 
of cells displaying Perls’ staining was significantly 
higher when derived from spheres treated under the 4 Hz 
condition (54.4 ± 7.1%) compared to the no field 
condition (35.2 ± 4.6%) (Figure 3D), with cells derived 
from the 4Hz condition appearing to show larger  
 
intracellular particle accumulations as well (Figure 3B, 
inset). 
Lumirem labelling of neurospheres is safe and does 
not affect neurosphere growth 
 Based on the results from the labelling study, which 
show evidence of Lumirem toxicity in NSCs cultured as 
monolayers, safety assays were performed only on the 
neurosphere population after labelling. No significant 
differences were found in neurosphere counts per unit 
area (Figure 4A) or size (Figure 4B) across treatment and 
field conditions, indicating that Lumirem treatment did 
not affect the proliferative capacity of NSCs. 
Cytotoxicity analyses of pyknotic nuclei revealed no 
significant differences between Lumirem-treated and 
untreated (control) NSCs, suggesting Lumirem added at 
an iron concentration of 10 µg/ml is non-toxic to NSCs 
labelled as neurospheres. Further, pyknotic nuclei counts, 
indicative of dying cells, were low across all conditions 
with a range from 2-5% (Figure 4C). NSCs were >95% 
positive for nestin and 100% positive for sox-2, 
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Figure 4. Bar charts displaying (A) neurosphere number per field (B) neurosphere size and (C) 
pyknotic nuclei after treatment under all conditions. Bar charts displaying the percentage of NSCs 
positive for (D) nestin and (E) Sox-2 after treatment under all conditions. (F) Quantification of the 
percentage of each daughter cell type generated from NSCs after treatment under all conditions. 
Representative double merged images of (G) nestin and (G –inset) sox-2 positive NSCs labelled 
under the 4 Hz oscillating magnetic field condition. Representative double merged images of (H) 
neurons, (I) astrocytes and (J) oligodendrocytes generated from NSCs labelled with Lumirem under 
the 4 Hz oscillating magnetic field condition. 
indicating that NSC stemness was not affected (Figures 
4D-E, G).  
The differentiation potential of NSCs is unaffected by 
Lumirem labelling 
Following differentiation, no significant differences were 
found in the proportions of neurons, astrocytes or 
oligodendrocytes generated between Lumirem-treated 
and untreated (control) NSCs (Figures 4F, H-J), 
indicating that Lumirem labelling does not affect NSC 













































For the first time, we have performed a direct comparison 
between two globally used NSC culture formats to assess 
the use of oscillating magnetic assistive technology on 
the uptake of an FDA approved clinical-grade MNP. The 
clinical use of Lumirem, its superparamagnetic properties 
and the lack of literature investigating its uptake in neural 
cell types led us to investigate this MNP in the current 
study. Lumirem uptake has only been studied in retinal 
pigment epithelial (ARPE19) cells for translational 
purposes in retinal diseases so far; the cells were cultured 
as monolayers however no field application was used in 
this study.30 The use of primary NSCs in our study, as 
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Figure 5. Schematic diagram outlining Lumirem labelling 
of neurospheres versus monolayers (top), and the effect of 
an oscillating magnetic field to enhance Lumirem uptake 
into NSCs cultured as neurospheres (bottom). 
opposed to cell lines, increases the biological relevance 
and validity of the results as cell lines tend to behave in a 
homogenous and clonal manner and are typically 
immortal having undergone many passages. They also 
show resistance to cell death, reducing their utility for 
translational studies.31 Our findings demonstrate that 
applied oscillating magnetic fields safely enhance 
particle uptake in a major neural transplant population 
propagated as suspension (but not adherent) cells, with 
no adverse effects on key regenerative properties of the 
labelled cells.  
Neurospheres offer multiple advantages from a 
transplantation perspective (summarised in Figure 1). 
First, neurospheres contain a high cell density within a 
small surface area, meaning greater numbers of NSCs 
can be labelled without the use of extensive culture 
equipment.20 Second, neurospheres have greater survival 
rates post-transplantation,27 vital for successful cell 
therapy. Neurospheres are also technically easy to 
culture, circumventing issues related to appropriate cell 
density and adherence encountered with the monolayer 
culture format. 
 The mechanism by which the oscillating magnetic 
field enhances Lumirem labelling of NSCs is poorly 
understood. A combination of enhanced sphere 
sedimentation in conjunction with MNP-membrane 
stimulation by oscillating fields may offer a reasonable 
explanation (Figure 5). Interestingly, the inner two thirds 
of neurospheres were more densely labelled compared to 
the periphery, which may be explained by neurosphere 
biology. MNPs became associated with small 
neurospheres at 24 hours following incubation. These 
cells, which form the central portion of the neurosphere 
are more highly phagocytic of apoptotic cells.33 
Additionally, NSCs towards the periphery of 
neurospheres display greater mitotic activity33 explaining 
the lower density labelling towards peripheries. 
Therefore, for clinical translation of this labelling method 
to be successful, neurosphere sizes would have to be 
controlled prior to transplantation procedures, in order to 
achieve optimal labelling efficiency.  
 
From the MNP aggregation and loss of cell viability 
observed following MNP and field application to 
adherent cells, we conclude that a monolayer culture 
format is not appropriate for Lumirem labelling of NSCs. 
The underlying basis for these effects is currently 
unclear. This could be explained by either a physical 
disruptive mechanism or an effect on NSC surface 
membranes. The former is evident by the loss of NSC 
adherence, which was noted to be increased by the 
presence of an oscillating magnetic field. Here, the chain-
like formations of Lumirem MNPs may cause high 
mechanical stress on NSC membranes and consequent 
loss of adherence, which is further exacerbated by 
stimulation under an oscillating magnetic field. 
Additionally, the effect of MNP chains coating NSC 
membrane surfaces may impede the uptake of smaller 
MNP aggregates by creating a physical barrier. We have 
not been able to find any other studies investigating the 
influence of a monolayer format on magnetolabelling 
with MNPs, and further investigations in this regard 
would yield interesting data. By contrast, it should be 
noted that transfection grade MNPs yield highly effective 
transfection in monolayers compared with neurospheres 
(manuscript submitted to Nanomedicine:NBM), 
highlighting the need to study variations in the uptake of 
different MNP classes in neural cells, for tissue 
engineering applications.  Although oscillating fields 
enhance particle uptake in neurospheres, multiple 
strategies could be employed to further enhance labelling 
efficacy- employed either independently or in 
combination depending on their safety and efficacy. 
These could include: increased particle concentrations 
and incubation times (Table 1); integrated methods for 
cell separation and particle labelling such as that used by 
the ‘Magselectofection’32 technique; and use of novel 
magnetic assistive devices with a range of oscillation 
formats, with testing of their imaging potential. A 
systematic study is also required to test neural transplant 
cell labelling with a range of clinical contrast agents, to 
identify those most compatible with magnetic assistive 
technology, whilst offering acceptable safety profiles.  
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Table 1. Increasing MNP concentration and incubation time can enhance MNP uptake into NSCs. 
Conclusions 
In summary, we have demonstrated that applied oscillating 
magnetic fields can be used to safely enhance the uptake of 
Lumirem, a clinical grade MNP, into NSCs propagated as 
neurospheres, for MRI tracking purposes following 
transplantation. By contrast, we conclude that the monolayer 
culture format is not compatible with this labelling approach, 
highlighting the important influence of cell culture growth 
method on the efficacy of magnetic assistive technology 
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